Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

Rosetta and Moffitt Partner to Develop microRNA Cancer Diagnostic

By Labmedica International staff writers
Posted on 16 Jun 2014
Rosetta Genomics, Ltd. (Princeton, NJ, USA; Rehovot, Israel), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, has entered into an agreement with Moffitt Cancer Center (Tampa, FL, USA) to advance the development and commercialization of Rosetta's thyroid neoplasia assay. Rosetta will work with Marino Leon, MD, associate member of the department of anatomic pathology at Moffitt.

Kenneth A. Berlin, president and CEO of Rosetta Genomics commented, “Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid fine-needle aspirations [FNAs] in various sample types and in a way consistent with common clinical practices. This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015.”

Dr. Marino Leon noted, “Many patients with indeterminate thyroid FNA results are sent to surgery as a precaution, despite the fact that the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars.”

Rosetta Genomics cancer tests are a series of microRNA-based diagnostic testing services. The Rosetta Cancer Origin test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The company’s assays are offered directly by Rosetta Genomics in the United States, and through distributors around the world. Rosetta’s cancer testing services are commercially available through its Philadelphia (PA, USA)-based College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified lab.

Rosetta’s research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.

Moffitt is one of only 41 US National Cancer Institute-designated comprehensive cancer centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in US News & World Report as one of “America's Best Hospitals” for cancer since 1999.

Related Links:

Rosetta Genomics
Moffitt Cancer Center



PURITAN MEDICAL
Sekisui Diagnostics
EUROIMMUN AG
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Technology

view channel
Image:  The Becton Dickinson fluorescent activated cell sorter FACScan (Photo courtesy of the Albert Einstein College of Medicine).

Noninvasive Method Captures Circulating Tumor Cells

A clinically proven, noninvasive fluorescence virus-guided capture system of human colorectal circulating tumor cells (CTCs) from blood samples for genetic testing has been introduced. This noninvasive... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.